There are a total of 12 candidates in mid to late-stage trials for ALS poised to enter the market in the next five years.

Prime Medicine has received the first-ever IND from the FDA for a prime editing drug which it is investigating in chronic ...

Eli Lilly’s merestinib has seen its Phase Transition Success Rate (PTSR) drop after an investigator-led Phase II trial of the ...

Klineo plans to expand its AI platform to include all cancers in France by the end of 2024, and eventually other countries ...

The expanded approval of Biktarvy was based on the Phase I trial data showing efficacy in pregnant HIV patients with ...

The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with ...

There are more than 50 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in clinical development for Type 2 diabetes, ...

PhaseV will use its ML-based technology to design the trial and Quanticate will help sponsors execute the trial.

Exeliom is running three Phase II trials of the candidate in three oncology indications but will focus on the gastric cancer ...

While the decentralisation of clinical trials has been happening for a while, many in the industry are still not moving with the tide according to MindMed executive director Lysa Triantafillou.

The central nervous system is the most researched therapy area for DCT trials with 26% of trials, followed by metabolic ...

J&J and Addex first partnered in 2004 to develop the positive allosteric modulator (PAM) of metabotropic glutamate receptor-2 (mGlu2 receptor), ADX71149 (JNJ-40411813). Image Credit: SERSOLL / ...